October 11, 2025Scientific ReportsOpen Access

Serum KL-6 as a biomarker to predict progression at one year in interstitial lung disease

View Full Paper

Ask AI

Bookmark

Serum KL-6 can effectively predict disease progression in interstitial lung disease at one year.
37% of ILD patients experienced progression after one year based on KL-6 measurement.
A risk score model combining KL-6 with age, gender, BMI, and FVC showed improved predictive accuracy.
Risk stratification based on KL-6 levels enhances assessment of progression risk in interstitial lung disease patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Observational analysis identifies serum KL-6 and clinical variables predicting progression in ILD, suggesting improved risk stratification.

Bonella et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis identifies serum KL-6 and clinical variables predicting progression in ILD, suggesting improved risk stratification.